Archives

The 2023 MDA Clinical & Scientific Conference is just around the corner. With 32 sessions, 184 speakers, 61 exhibitors and patient advocacy organizations and 14 Industry Forums, this year’s conference…

On Feb. 28, the US Food and Drug Administration (FDA) granted approval to omaveloxolone (SKYCLARYS™) for the treatment of Friedreich’s ataxia (FA) in adults and adolescents aged 16 years and…

By thinking about personal safety and learning about self-defense with a disability, you can feel more protected and confident outside your home.

Facioscapulohumeral muscular dystrophy (FSHD) is a rare genetic disorder that affects the muscles of the face (facio), shoulders (scapulo), and upper arms (humeral). It is one of the most common…

New therapies and research advances for some neuromuscular diseases are paving the way for developing new treatments for other rare diseases.

Leah is an MDA National Ambassador who lives with a rare form of neuromuscular disease. Dear Parents, Hi,  my name is Leah and I am 15 years old. I live…

For our February Valentine’s Day Quest Podcast, we catch up with Bill Crossland, a writer, director, producer, and actor who lives with muscular dystrophy. Bill shares his insights and experiences…

MDA Summer Camp is a magical place where truly anything is possible. Every summer, youth living with neuromuscular diseases have the opportunity to attend week-long sessions of overnight camp filled…

MDA’s mission is to empower the people we serve to live longer, more independent lives. One way that we do this is through support-centered check-in calls and touchpoints. In line…

Public transportation can mean independence for people with disabilities if you know how to use it — and how to advocate for accessibility.